momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (11825)	11/13/2018 1:19:23 PM
From: tuck	Read Replies (2) of 12215

GLMD: Signal looks rather weak on liver fat reduction and fibrosis scores. 600mg cohort had higher liver fat to start with, but less reduction than 400mg cohort. Not sure how to interpret that. Dose response doesn't look right on primary endpoint. Frankly don't understand why the stock is holding, while MDGL and VKTX continue to sell off or rise minimally from data that seemed at least as good as expectations for both. Discontinuation rate and SAE profile looks pretty good, but there are clearly some that are attributable to the drug, such as infections and headache. So, maybe a role in combination? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next